J9300 gemtuzumab ozogamicin HCPCS Reimbursement

HCPCS Level II code J9300 denotes the injection of gemtuzumab ozogamicin, 5 mg, an antineoplastic agent used in oncology care. Nationally, this code matters for providers, payers, and patients because it captures administration of a high-cost, specialty injectable therapy that is typically delivered in outpatient infusion settings. Accurate coding affects coverage determinations, billing consistency, and claims processing for complex cancer treatments.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the payer landscape. The publication outlines benchmark topics such as coverage patterns, prior authorization trends, and common billing considerations for oncology injectables, and summarizes recent policy updates that influence reimbursement and utilization management for specialty chemotherapy agents.

The piece also provides practical references for revenue cycle and clinical staff: how the code is used on service lines, implications for claims submission, and what to expect from major payers regarding authorization and claims adjudication. Data not provided in the input (for example, modifiers, associated taxonomies, and specific ICD-10 pairings) are noted as unavailable where relevant.

Billing Code Overview

HCPCS Level II code J9300 represents the injection of gemtuzumab ozogamicin, 5 mg. This code is used to bill for administration of the specified dose of gemtuzumab ozogamicin, a targeted anti-cancer antibody-drug conjugate.

Service type: Injectable chemotherapy / antineoplastic agent administration

Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or oncology clinic

Data not available in the input.

Clinical Context

A typical patient is an adult with relapsed or refractory acute myeloid leukemia (AML) or CD33-positive myeloid malignancy being treated with targeted antibody–drug conjugate therapy. The patient presents to an oncology infusion center for administration of J9300 (injection, gemtuzumab ozogamicin, 5 mg). Prior to infusion, the clinical workflow includes review of current hematologic status, recent complete blood count, liver function tests, coagulation profile, and review of prior therapies. A prescribing oncologist documents indication, dose calculation based on body weight or body surface area, and premedication orders (e.g., acetaminophen, antihistamine, corticosteroid) as indicated. Nursing performs baseline vital signs, establishes IV access, and prepares gemtuzumab ozogamicin per institutional pharmacy protocols. The medication is administered intravenously over the recommended infusion time with monitoring for infusion-related reactions and hepatotoxicity. Post-infusion observation includes vital signs, assessment for adverse events (e.g., infusion reaction, veno-occlusive disease), documentation of lot number and dose administered, and scheduling of follow-up labs and subsequent doses as part of the treatment plan. Typical site of service is an outpatient hospital infusion center or outpatient oncology clinic. The procedure is provided by oncology physicians, advanced practice providers, oncology nurses, and specialty pharmacy services coordinating preparation and administration.

Coding Specifications

Modifier	Description	When to Use
`59`

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology & Oncology	Medical oncologists and hematologist-oncologists who prescribe and oversee gemtuzumab ozogamicin
`207Q00000X`	Medical Oncology	Oncology specialists managing systemic chemotherapy and targeted agents
`363A00000X`	Registered Nurse	Oncology infusion nurses who administer IV therapies and monitor patients
`364S00000X`	Clinical Nurse Specialist	Advanced practice nursing roles in oncology infusion management
`207L00000X`	Oncology Nurse Practitioner	Advanced practice providers who prescribe and manage infusion regimens

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C92.30`	Acute myelogenous leukemia, not having achieved remission	AML indication where gemtuzumab ozogamicin may be used for relapsed/refractory disease
`C92.31`	Acute myelogenous leukemia, in remission	Used when ongoing management or consolidation therapy with targeted agents is part of remission strategy
`C92.40`	Acute myelomonocytic leukemia, not having achieved remission	AML subtype potentially treated with CD33-targeted therapy
`C92.41`	Acute myelomonocytic leukemia, in remission	Post-treatment management or consolidation setting
`C92.89`	Other specified myeloid leukemia	Other myeloid leukemias with CD33 expression where targeted therapy may be considered
`D61.9`	Aplastic anemia, unspecified	Listed as supportive context when cytopenias complicate AML treatment decisions
`Z51.11`	Encounter for antineoplastic chemotherapy	General encounter code for administration of chemotherapy or targeted antineoplastic therapy
`Z51.12`	Encounter for antineoplastic immunotherapy	Encounter code appropriate when biologic targeted therapy is administered

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Used for billing the infusion administration time for a single-agent IV chemotherapy or biologic when infusion duration fits the code definition
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary infusion)	Used when the infusion extends beyond the initial hour and additional time-based billing is required
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May be used for initial therapeutic infusions in certain outpatient settings depending on payer rules
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used for additional infusion time beyond the initial hour
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	May be used if supportive injections (e.g., growth factors or other parenteral supportive meds) are administered during the visit

OpenPayer

Summary & Overview

HCPCS Level II J9300: Injection, gemtuzumab ozogamicin, 5 mg